Clioquinol 3% / Coal Tar 3% in Betamethasone valerate 0.025% ointment
Requires a prescription from a doctor or prescriber
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing all 32 studies.
Randomised trials: 1 · 1912–2026
Showing all 32 studies, sorted by most relevant.
S. Khandpur, K. Sahni
Indian Journal of Dermatology, 2014
R. Dhurat, Richa Sharma
Journal of Hair Restoration and Regenerative Medicine, 2026
Alopecia areata (AA) is an autoimmune disorder characterized by patchy, non-scarring hair loss. Anthralin (dithranol) is a topical irritant that has shown efficacy in treating AA. Despite its therapeutic potential, there is a common belief that combining steroids with dithranol may reduce its effectiveness. This report presents a case of alopecia totalis in which a combination of systemic steroids and dithranol was used with a synergistic therapeutic effect. A 12-year-old boy with a six-month history of complete scalp hair loss was diagnosed with alopecia totalis. He was treated with betamethasone pulse therapy and Derobin TM ointment (a combination of coal tar, salicylic acid, and dithranol) and applied to both halves of the scalp on a rotational basis. The patient misunderstood the instructions, applying the ointment only to one side while taking systemic steroids. After 2 months, hair regrowth was observed exclusively on the treated side, demonstrating the potential synergistic effect of the combined treatment. Anthralin promotes hair regrowth by inhibiting pro-inflammatory cytokines, while steroids also reduce these cytokines, suggesting a possible synergistic effect. Our case highlights that combining systemic steroids with dithranol can reduce irritation, improve compliance, and enhance hair regrowth. The findings suggest that this combination could be effective for managing severe AA with minimal side effects. The combination of dithranol and systemic steroids may offer a promising approach to treating alopecia areata, enhancing regrowth while minimizing irritation.
Abstract licence: CC BY-NC-SA
Oxford English Dictionary, 2026
G. P. Thami, R. Sarkar
Clinical and Experimental Dermatology, 2002
María Antonia Diez, Roberto Garcia
New Trends in Coal Conversion, 2019
Definitions, 2020
The Fairchild Books Dictionary of Textiles, 2021
Nicholas J. Lowe
Archives of Dermatology, 1982
Prasutr Thawornchaisit, Kitiphong Harncharoen
Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2007
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.